BLAINJECTIONSOLUTION1 Generic Approved
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
XTRENBO (denosumab-qbde) by Hikma is rank ligand blocking activity [moa]. First approved in 2025.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XTRENBO (denosumab-qbde) is a monoclonal antibody that blocks RANK ligand, a key mediator of bone resorption, approved by the FDA on September 26, 2025. It treats a broad spectrum of bone-related conditions including osteoporosis, giant cell tumor of bone, multiple myeloma, bone metastases across solid tumors, and bone loss associated with systemic diseases. The mechanism reduces osteoclast formation and activity, thereby increasing bone mineral density and reducing fracture risk.
Launch
As a newly launched biosimilar entering a competitive landscape dominated by peak-revenue innovators, XTRENBO will require aggressive commercial infrastructure building and market penetration strategies to establish share.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
XTRENBO launch positions professionals in high-intensity commercial roles focused on payer negotiation, physician education on biosimilar equivalence, and market share capture from established reference products. Career growth depends heavily on successful penetration in competitive oncology and orthopedic segments and execution of rapid market access strategies.
Brand Manager
Worked on XTRENBO at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.